📰 Development Profile News
Development Profile News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Development Profile. Real-time updates on events, politics, business and more.
March 28, 2023
IOnctura, a clinical stage biotechnology company developing breakthrough therapies for patients suffering with cancer, today announces that the innovative medicine designation, the Innovation Passport, has been awarded for roginolisib, for the...
February 27, 2023
/PRNewswire/ -- AMO Pharma Limited ("AMO Pharma"), a privately held biopharmaceutical company focusing on rare childhood-onset neurogenetic disorders with...
January 15, 2023
Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema - read this article along with other careers information, tips and advice on BioSpace
February 5, 2022
The supply can't keep up with the demand. Executive Director of Alexandria Area Economic Development Commission Nicole Fernholz says the city is working aggressively to ensure enough affordable housing.
January 1, 2021
Date Time MHRA Innovative Licensing and Access Pathway is open for business The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with improved efficiency and flexibility, readying the MHRA for a new era in medicines approvals in the UK. Central to realising this ambition is how the ILAP provides a single inte...
January 1, 2021
The MHRA Innovative Licensing and Access Pathway is open for business The Medicines and Healthcare products Regulatory Agency (MHRA) today, 1 January 2021, formally starts the Innovative Licensing and Access Pathway (ILAP). From: 1 January 2021 The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with i...
January 1, 2021
Source: UK Government The ambition of this new licensing and access pathway is to reduce the time to market for innovative medicines. The ILAP combines the MHRA’s globally recognised strengths of independence and high standards of quality, safety, and efficacy, with improved efficiency and flexibility, readying the MHRA for a new era in medicines approvals in the UK. Central to realising this ambition is how the ILAP provides a single integrated platform for sustained collaborative working be...